TEVA-CLOPIDOGREL TABLET

Šalis: Kanada

kalba: anglų

Šaltinis: Health Canada

Nusipirk tai dabar

Parsisiųsti Prekės savybės (SPC)
12-01-2023

Veiklioji medžiaga:

CLOPIDOGREL (CLOPIDOGREL BISULFATE)

Prieinama:

TEVA CANADA LIMITED

ATC kodas:

B01AC04

INN (Tarptautinis Pavadinimas):

CLOPIDOGREL

Dozė:

75MG

Vaisto forma:

TABLET

Sudėtis:

CLOPIDOGREL (CLOPIDOGREL BISULFATE) 75MG

Vartojimo būdas:

ORAL

Vienetai pakuotėje:

30/100/500

Recepto tipas:

Prescription

Gydymo sritis:

PLATELET AGGREGATION INHIBITORS

Produkto santrauka:

Active ingredient group (AIG) number: 0134440001; AHFS:

Autorizacija statusas:

APPROVED

Leidimo data:

2011-12-14

Prekės savybės

                                TEVA-CLOPIDOGREL (Clopidogrel Tablets)
_ _
Page 1 of 68
_ _
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TEVA-CLOPIDOGREL
Clopidogrel Tablets
Tablets, 75 mg and 300 mg clopidogrel (as clopidogrel bisulfate), Oral
Teva Standard
Platelet Aggregation Inhibitor
Teva Canada Limited
30 Novopharm Court
Toronto, Ontario
M1B 2K9
Canada
www.tevacanada.com
Submission Control Number: 267470
Date of Initial Authorization:
December 14, 2011
Date of Revision:
January 12, 2023
TEVA-CLOPIDOGREL (Clopidogrel Tablets)
_ _
Page 2 of 68
_ _
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Endocrine and Metabolism
03/2021
7 WARNINGS AND PRECAUTIONS, Hematologic
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL
CHANGES…………………………………………………………..………………………………..2
TABLE OF
CONTENTS……………………………………………………………………………………………………………....2
PART I: HEALTH PROFESSIONAL
INFORMATION……………………………………………………………………...4
1
INDICATIONS……………………………………………………………………………………………………………………...4
1.1
Pediatrics…………………………………………………………………………………………………………………………4
1.2
Geriatrics…………………………………………………………………………………………………………………….…..4
2
CONTRAINDICATIONS………………………………………………………………………………………………………...5
4 DOSAGE AND
ADMINISTRATION………………………………………………………………………………...........5
4.2
Recommended Dose and Dosage
Adjustment………………………………………………………………….5
4.4
Adm
                                
                                Perskaitykite visą dokumentą
                                
                            

Dokumentai kitomis kalbomis

Prekės savybės Prekės savybės prancūzų 12-01-2023

Ieškokite perspėjimų, susijusių su šiuo produktu

Peržiūrėti dokumentų istoriją